Hepatitis E vaccine recombinant (Xiamen Innovax)

重组戊型肝炎疫苗（厦门万泰沧海生物技术有限公司）

Report date: 2025/09/10 16:17:36

Base Information

Drug NameHepatitis E vaccine recombinant (Xiamen Innovax)

Drug Alias NameHEV-239重组戊型肝炎疫苗益可宁Hecolin

ClassificationVaccines > National Immunization Program > Non-immunization program vaccine(Class II)Vaccines > Application > Prophylactic vaccineVaccines > Development/production technology > Genetically engineered subunit vaccine

Mechanisms of ActionImmunostimulants

TargetsNot applicable

Therapy Area/IndicationsHepatitis E

Global Approved IndicationsHepatitis E

Approved Indications in ChinaHepatitis E

Original Approved Country/TerritoryMainland China

Original Approved Date2011/12/01

Country/TerritoryUnited StatesPakistanSouth Africa +[4]

CombinationsNo

Global Highest StatusApproved

Highest Status in ChinaApproved

Originator CompaniesXiamen Innovax Biotech Co Ltd Xiamen University

China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesInternational Vaccine Institute Xiamen Innovax Biotech Co Ltd

Inactive CompaniesXiamen University National Institute Of Allergy And Infectious Diseases (Niaid)Beijing Wantai Biological Pharmacy Enterprise Co Ltd

Active IndicationsHepatitis E

Inactive IndicationsN/A

Other Information

ATC CodeJ07BC